Stem cell therapy and its potential role in pituitary disorders

Current Opinion in Endocrinology, Diabetes, and Obesity
Montserrat Lara-VelazquezAlfredo Quiñones-Hinojosa


The pituitary gland is one of the key components of the endocrine system. Congenital or acquired alterations can mediate destruction of cells in the gland leading to hormonal dysfunction. Even though pharmacological treatment for pituitary disorders is available, exogenous hormone replacement is neither curative nor sustainable. Thus, alternative therapies to optimize management and improve quality of life are desired. An alternative modality to re-establish pituitary function is to promote endocrine cell regeneration through stem cells that can be obtained from the pituitary parenchyma or pluripotent cells. Stem cell therapy has been successfully applied to a plethora of other disorders, and is a promising alternative to hormonal supplementation for resumption of normal hormone homeostasis. In this review, we describe the common causes for pituitary deficiencies and the advances in cellular therapy to restore the physiological pituitary function.


Aug 13, 1977·British Medical Journal·G V VimpaniJ W Farquhar
Jun 15, 1989·Nature·E BorrelliR M Evans
Jul 1, 1973·Journal of Neurosurgery·A M Landolt
Jan 1, 1980·Virchows Archiv. A, Pathological Anatomy and Histology·W Saeger, H Warnecke
Jul 1, 1994·The Journal of Pediatrics·R LindsayM Rallison
Aug 15, 2002·The Journal of Endocrinology·A Levy
Sep 14, 2002·Ultrastructural Pathology·Eva Horvath, Kalman Kovacs
Nov 5, 2002·Nature Reviews. Cancer·Sylvia L Asa, Shereen Ezzat
May 27, 2005·Experimental Cell Research·Diana A LeporePaul Q Thomas
Sep 10, 2005·Reviews in Endocrine & Metabolic Disorders·Karine Rizzoti, Robin Lovell-Badge
Dec 2, 2005·The Journal of Comparative Neurology·Alfredo Quiñones-HinojosaArturo Alvarez-Buylla
Jul 1, 2006·Nature·Thomas A Rando
Mar 6, 2007·Neuroendocrinology·Hugo Vankelecom
Mar 31, 2007·Stem Cells·Diana A LeporePaul Q Thomas
Apr 27, 2007·Experimental Neurology·Alfredo Quiñones-Hinojosa, Kaisorn Chaichana
Jul 7, 2007·Physiological Reviews·Xiaoyan ZhuMichael G Rosenfeld
Dec 18, 2007·Journal of Neuroendocrinology·Andy Levy
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·Teddy FauquierIain C A F Robinson
Apr 26, 2008·Proceedings of the National Academy of Sciences of the United States of America·Anatoli S GleibermanGrigori Enikolopov
Dec 6, 2008·Science·J M W Slack
Mar 19, 2009·Endocrine Development·Ken H Darzy, Stephen M Shalet
May 7, 2009·Stem Cells·Jianghai ChenHugo Vankelecom
Oct 20, 2009·Endocrine Reviews·Daniel KelbermanMehul T Dattani
Nov 18, 2009·General and Comparative Endocrinology·Hugo Vankelecom, Lies Gremeaux
Jul 24, 2010·Neurosurgery·João Paulo C de AlmeidaAlfredo Quiñones-Hinojosa
Sep 28, 2010·Journal of Neurosurgery·Gabriel ZadaEdward R Laws
Dec 15, 2010·The European Journal of Neuroscience·Hugo Vankelecom
Apr 16, 2011·Endocrine Reviews·Frederic CastinettiSally A Camper
Jul 2, 2011·Proceedings of the National Academy of Sciences of the United States of America·Sally A Camper
Dec 2, 2011·Nature·Karine Rizzoti, Robin Lovell-Badge
Mar 23, 2012·Trends in Endocrinology and Metabolism : TEM·P MollardJacques Drouin
Sep 18, 2012·Frontiers in Neuroendocrinology·P R Le TissierP Mollard
Feb 21, 2013·Pituitary·Farshad NassiriRicardo V Lloyd
Sep 3, 2013·Molecular and Cellular Endocrinology·Hugo Vankelecom, Jianghai Chen
Oct 10, 2013·QJM : Monthly Journal of the Association of Physicians·V WilsonD E Price
Jan 10, 2014·Pituitary·Nestoras MathioudakisAlfredo Quiñones-Hinojosa
Jan 7, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wassim ChemaitillyCharles A Sklar
Feb 7, 2015·The Journal of Clinical Endocrinology and Metabolism·Joseph M PappachanRichard N Clayton
Jul 15, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Whitney W WoodmanseeAACE Neuroendocrine and Pituitary Scientific Committee
Oct 27, 2015·Clinical Endocrinology·Nikolaos KyriakakisRobert D Murray
Jan 15, 2016·Nature Communications·Chikafumi OzoneYoshiki Sasai
Nov 30, 2016·Acta Neuropathologica Communications·Branavan ManoranjanSheila K Singh
Jan 28, 2017·Medicina clínica·Juan A GuadixPatricia Gálvez-Martín
Feb 17, 2017·EMBO Reports·Jing Nie, Eri Hashino
Mar 8, 2017·Cellular Reprogramming·Farzaneh RamiRasoul Salehi


Dec 21, 2017·Brain Sciences·Montserrat Lara-VelazquezAlfredo Quiñones-Hinojosa

Related Concepts

Adenohypophyseal Diseases
Pituitary Stalk
Natural Regeneration
Hormone Replacement Therapy
Stem Cell Transplant
Cell- and Tissue-Based Therapy
Pituitary Diseases

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

CA: a Cancer Journal for Clinicians
W W Loui
Reproduction : the Official Journal of the Society for the Study of Fertility
Henry N JabbourJane E Norman
© 2021 Meta ULC. All rights reserved